BioSpace News Archive

Lead Therapeutic Targeting the Main Source of Cortisol Toxicity to be Studied in Phase 2 Trial for Cushing Syndrome

Moderna and South Korea will explore potential areas of collaboration for research and development of mRNA vaccines and local manufacturing opportunities in South Korea

In a pre-specified analysis of the Phase 2 SERENITY study, Eli Lilly and Company’s mirikizumab improved fatigue in patients with moderately to severely active Crohn’s disease at 12 weeks, as measured by the mean change in FACIT-Fatigue scores compared to placebo, with improvements that were sustained up to one year.

The agreement will further enable global supply of mRNA-1273, Moderna’s COVID-19 vaccine with Samsung Biologics’ fill and finish manufacturing service

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.

HAV performance in the clinical setting as an arteriovenous reconstruction underscores the potential for use as vascular access conduits for dialysis patients

Dengue is the fastest-spreading mosquito-borne viral disease with an estimated 390 million cases and 500,000 hospitalizations per year globally, with limited options for prevention

Interim analysis of the Phase 3 PUNCH™ CD3-Open-Label Study (OLS) showed positive efficacy and consistent safety with RBX2660 for up to six months in patients with recurrent Clostridioides difficile (C. difficile) infection, adding to robust evidence of largest clinical development program in microbiome-based therapeutics

Novavax, Inc. announced the signing of a non-binding memorandum of understanding with the Ministry of Health and Welfare of Korea and SK bioscience, Co. Limited, a vaccine business subsidiary of SK Group, to explore further cooperation in the development and manufacturing of vaccines, including NVX-CoV2373, Novavax’ recombinant protein COVID-19 vaccine candidate.